(RTTNews) - Shares of Lipocine Inc. (LPCN) are falling about 78 percent on Thursday morning trading following the announcement of topline results from its Phase 3 placebo-controlled trial, which failed to meet the primary endpoint. The trial evaluated LPCN 1154 or oral brexanolon
1 views
Lipocine Stock Tanks 78% After Phase 3 Oral Brexanolone Trial Failed To Meet Primary Endpoint
(RTTNews) - Shares of Lipocine Inc. (LPCN) are falling about 78 percent on Thursday morning trading following the announcement of topline results from its Phase 3 placebo-controlled trial, which failed to meet the…
